Research programme: RNA-based therapeutics - Janssen Vaccines and Prevention/Synthetic Genomics

Drug Profile

Research programme: RNA-based therapeutics - Janssen Vaccines and Prevention/Synthetic Genomics

Alternative Names: Cancer therapeutics - Janssen Vaccines & Prevention B.V./Synthetic Genomics; Infectious disease RNA-based therapeutics - Janssen Vaccines & Prevention B.V./Synthetic Genomics; RNA-based medicines - Janssen Vaccines & Prevention B.V./Synthetic Genomics; RNA-based therapies - Janssen Vaccines & Prevention B.V./Synthetic Genomics; RNA-based vaccines - Janssen Vaccines & Prevention B.V./Synthetic Genomics

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synthetic Genomics
  • Developer Janssen Vaccines and Prevention B.V; Synthetic Genomics
  • Class Anti-infectives; Antineoplastics; RNA vaccines
  • Mechanism of Action Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Infections

Most Recent Events

  • 05 Jan 2017 Early research in Cancer in USA (Parenteral)
  • 05 Jan 2017 Early research in Infections in USA (Parenteral)
  • 05 Jan 2017 Synthetic Genomics and Janssen Vaccines and Prevention B.V. agree to co-develop RNA-based therapeutics for Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top